抗逆转录病毒药物市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按药物类别(整合酶抑制剂、蛋白酶抑制剂、多类组合产品、核苷类逆转录酶抑制剂、非核苷类逆转录酶抑制剂等)和地理划分

市场快照

Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.0 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

抗逆转录病毒药物是治疗艾滋病毒的药物。促成市场增长的因素包括艾滋病毒负担的增加、研发投资的增加以及疗效更好的新药的增加。根据美国卫生与公众服务部的数据,全世界约有 3790 万人感染了 HIV/AIDS。2018 年,全球估计有 170 万人新感染了 HIV。抗逆转录病毒药物 (ARV) 是 HIV/AIDS 管理的基础,因为目前尚无治疗 HIV 的药物或疫苗。在携带非耐药性 HIV 毒株的个体中,抗逆转录病毒治疗可以抑制约 80% 的 HIV 复制。这个庞大的患者群表明,抗逆转录病毒药物市场预计将在预测期内增长。

报告范围

根据报告的范围,抗逆转录病毒药物是用于治疗逆转录病毒感染的药物,主要是 HIV。逆转录病毒是属于逆转录病毒科的一组病毒, 它们 以核糖核酸 (RNA) 的形式典型地携带其遗传蓝图。抗逆转录病毒药物阻碍了这些病毒的繁殖,而不是杀死它们。

By Drug Class
Protease Inhibitors
Integrase Inhibitors
Multi-class Combination Products
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

多类别组合产品预计在预测年份录得显着增长

根据药物类别,分为整合酶抑制剂、蛋白酶抑制剂、多类组合产品、核苷类逆转录酶抑制剂(NRTIs)、非核苷类逆转录酶抑制剂(NNRTIs)等。导致多类组合产品增长的关键因素是艾滋病毒和新药批准负担的增加。据世卫组织称,2018 年约有 770,000 人死于艾滋病毒。许多公司正专注于开发用于治疗抗逆转录病毒药物的突破性产品,以保持其竞争优势并打入新的区域市场。此外,对参与抗逆转录病毒药物研究的公司的资金增加预计将推动所研究的市场。

Anti-retroviral Drugs Market 1

北美在抗逆转录病毒药物市场占有最大份额

抗逆转录病毒药物市场在北美地区占有最大份额。根据美国卫生与公众服务部的数据,估计美国每年有超过 56,000 例新的 HIV 病例,每 100 名受感染的美国人中约有 20 人不知道自己感染了这种病毒。这一增长归因于 ART 的高覆盖率和对处方品牌药物的日益重视。此外,美国国立卫生研究院 (NIH) 是世界上对艾滋病毒/艾滋病研究的最大公共投资,预计将推动市场增长。

Anti-retroviral Drugs Market 2

竞争格局

目前抗逆转录病毒领域公司的需求正在通过合作、并购和探索新的地理区域来提高其研发能力。抗逆转录病毒药物市场的全球参与者有 - 艾伯维公司、勃林格殷格翰、百时美施贵宝、F. Hoffmann-La Roche Ltd、吉利德科学、默克公司、Mylan NV 和 ViiV Healthcare。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of HIV

      2. 4.2.2 Increasing Investment in R&D

      3. 4.2.3 Increase in Availability of Novel Drugs with Better Efficacy

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects of Drugs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Class

      1. 5.1.1 Protease Inhibitors

      2. 5.1.2 Integrase Inhibitors

      3. 5.1.3 Multi-class Combination Products

      4. 5.1.4 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

      5. 5.1.5 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

      6. 5.1.6 Others

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle-East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie Inc.

      2. 6.1.2 Boehringer Ingelheim International GmbH

      3. 6.1.3 Bristol-Myers Squibb Company

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 Gilead Sciences, Inc.

      6. 6.1.6 Merck & Co, Inc.

      7. 6.1.7 Mylan N.V.

      8. 6.1.8 ViiV Healthcare

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Anti-retroviral Drugs Market market is studied from 2018 - 2026.

The Anti-retroviral Drugs Market is growing at a CAGR of 4.0% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Merck & Co, Inc., ViiV Healthcare are the major companies operating in Anti-retroviral Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!